Skip to content

US · FBLG · BIOTECHNOLOGY

FibroBiologics, Inc. Common Stock (FBLG) intrinsic value and stock valuation

$0.71as of 2026-11-21 · Mkt cap 1.82M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

FibroBiologics, Inc. Common Stock DCF and intrinsic value

InvestorsCraft values FBLG with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from FBLG’s statements →

FibroBiologics, Inc. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Houston, TX 77598 fibrobiologics.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-18.65M
20202025
Free cash flow
-$-16.66M
20202025
Total equity
$6.16M
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-16.65M-$-13.74M-$-8.89M-$-4.47M-$-1.58M
Net income-$-18.65M-$-11.16M-$-16.48M-$-5.12M-$-1.58M
EPSd-$-8.36M-$-6.8M-$-10.17M-$-3.16M-$-975.31K
Operating cash flow-$-16.39M-$-11.9M-$-6.4M-$-4.07M-$-1.41M
Capital expenditure-$-260K-$-180K-$-490K$0.00$0.00
Free cash flow-$-16.66M-$-12.09M-$-6.9M-$-4.07M-$-1.41M
Total assets$9.62M$16.5M$11.8M$4.82M$470K
Total debt$2.41M$10.6M$1.75M$7.52M$1.3M
Net debt-$-2.48M-$-3.43M-$-7.42M$5.26M$890K
Total equity$6.16M$2.73M$1.25M-$-4M-$-1.29M
Cash and short-term investments$4.89M$14M$9.16M$2.27M$410K
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$830K$0.00$0.00$0.00$0.00
Gross profit-$-830K$0.00$0.00$0.00$0.00
Research and development expenses$7.41M$4.5M$2.37M$1.15M$520K
Selling, general and administrative expenses$9.24M$9.23M$6.52M$3.32M$1.06M
Other expenses-$-830K$0.00$0.00$0.00$0.00
Operating expenses$15.8M$13.7M$8.89M$4.47M$1.58M
Cost and expenses$16.7M$13.7M$8.89M$4.47M$1.58M
Interest income$250K$250K$0.00$0.00$0.00
Interest expense$200K$20K$150K$650K$0.00
Depreciation and amortization$830K$570K$440K$90K$0.00
Ebitda-$-17.61M-$-10.57M-$-15.9M-$-4.37M-$-1.58M
Operating income-$-16.65M-$-13.74M-$-8.89M-$-4.47M-$-1.58M
Total other income/expenses, net-$-2M$2.58M-$-7.6M-$-650K-$0.00
Income before tax-$-18.65M-$-11.16M-$-16.48M-$-5.12M-$-1.58M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-18.65M-$-11.16M-$-16.48M-$-5.12M-$-1.58M
Weighted average shares outstanding$2.23M$1.64M$1.62M$1.62M$1.62M
Weighted average diluted shares outstanding$2.23M$1.64M$1.62M$1.62M$1.62M
Balance sheet
20252024202320222021
Cash and short-term investments$4.89M$14M$9.16M$2.27M$410K
Net receivables$0.00$0.00$0.00$300K$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$6.35M$14.2M$9.21M$2.62M$470K
Property, plant and equipment, net$3.22M$2.22M$2.61M$2.2M$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$3.27M$2.22M$2.61M$2.2M$0.00
Total assets$9.62M$16.5M$11.8M$4.82M$470K
Accounts payable$940K$2.7M$1.44M$760K$230K
Short-term debt$710K$9.57M$360K$5.78M$1.3M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$1.76M$12.7M$9.18M$7.07M$1.76M
Long-term debt$1.7M$980K$1.39M$1.75M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.7M$980K$1.39M$1.75M$0.00
Capital lease obligations$2.41M$1.39M$1.75M$2.07M$0.00
Total liabilities$3.46M$13.7M$10.6M$8.82M$1.76M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-54.16M-$-35.52M-$-24.36M-$-7.87M-$-2.75M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$1.46M
Total equity$6.16M$2.73M$1.25M-$-4M-$-1.29M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$2.41M$10.6M$1.75M$7.52M$1.3M
Net debt-$-2.48M-$-3.43M-$-7.42M$5.26M$890K
Cash flow statement
20252024202320222021
Net income-$-18.65M-$-11.16M-$-16.48M-$-5.12M-$-1.58M
Depreciation and amortization$830K$570K$440K$90K$0.00
Stock-based compensation$2.69M$2.22M$1.76M$270K$0.00
Change in working capital-$-3.31M$560K$490K$310K$170K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$1.25M$670K$530K$0.00
Net cash provided by operating activities-$-16.39M-$-11.9M-$-6.4M-$-4.07M-$-1.41M
Investments in property, plant and equipment-$-260K-$-180K-$-490K$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-260K-$-180K-$-490K$0.00$0.00
Common stock issued$6.59M$7.51M$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$7.57M$16.9M$13.8M$5.92M$1.82M
Net change in cash-$-9.09M$4.82M$6.9M$1.86M$410K
Cash at end of period$4.89M$14M$9.16M$2.27M$410K
Operating cash flow-$-16.39M-$-11.9M-$-6.4M-$-4.07M-$-1.41M
Capital expenditure-$-260K-$-180K-$-490K$0.00$0.00
Free cash flow-$-16.66M-$-12.09M-$-6.9M-$-4.07M-$-1.41M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About FibroBiologics, Inc. Common Stock

        FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.

        CEO
        Peter O'Heeron
        Employees
        15
        Beta
        1.17

        Explore

        Frequently asked questions

        What is the intrinsic value of FibroBiologics, Inc. Common Stock (FBLG)?

        InvestorsCraft does not currently publish an intrinsic value for FBLG. How the IC value is calculated.

        Is FBLG undervalued?

        InvestorsCraft does not publish an undervaluation signal for FBLG at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.